Efficacy and Safety of Finerenone in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Trials

Rakhshanda khan[1], Vamsi Pachchipulusu[2] , Dharaneswari Hari Narayanan[3], Chidurala Rahul[4], Hanumanthu kavya tejaswini[5], Palak Patel[6], Raghu Vamsi Vanguru[7], Patel Yash Kalpeshbhai[8], Sowmiya Lakshmi[9], Nanditha Nandakishor[10], Harshawardhan Dhanraj ramteke[11], Abdus sameey[12]

1. Ayaan institute of medical sciences, Moinabad, India, doctorkhan0501@gmail.com
2. Ucf fort Walton , Fort Walton beach , Florida, USA, Vamsi.pachchipulusu@gmail.com
3. Omandurar Medical College, Chennai, India, dharnihari1210@gmail.com
4. Sri Ramachandra Institute of Higher Education and Research, Porur, India, ch.rahul03@gmail.com
5. GSL medical college Rajahmundry, India, Kavyatejaswini.h@gmail.com
6. GMERS medical college,Gotri , Vadodara, India, palakpatel1039@yahoo.in
7. konaseema institute of medical sciences, Vijaywada, India, raghuvamsivanguru@gmail.com
8. Tbilisi State Medical University, Tbilisi, Georgia, ypatelvsn201@gmail.com
9. Medical college Baroda, India, dr.sowmiya.r@gmail.com
10. JJM Medical College, Davangere. India, nanditha946@gmail.com
11. Anhui medical university, Hefei, China, Harshawardhanramteke7@gmail.com
12. College of medical sciences Chitwan , Bharatpur , Nepal , doctorabdus@gmail.com

Corresponding author
Vamsi Pachchipulusu
UCF fort Walton , Fort Walton beach
Florida, USA
Vamsi.pachchipulusu@gmail.com

Abstract

Introduction:

Heart failure with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF) accounts for nearly half of all heart failure cases, yet effective therapies remain limited. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, offers anti-fibrotic and anti-inflammatory effects with improved safety compared to steroidal MRAs. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of finerenone in HFpEF/HFmrEF.

Methods:

We systematically searched PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus through September 2025, including only randomized controlled trials. Data extraction and risk of bias (RoB 2) assessments were performed independently by two reviewers. Pooled log risk ratios **log (RR)** and 95% confidence intervals (CIs) were calculated using random-effects models.

Results:

Ten RCTs comprising 33,544 patients (20,279 males, 13,202 females) with a mean follow-up of 16.15 months were included. Finerenone significantly reduced major adverse cardiovascular events (MACE; log RR –0.11 [– 0.17, –0.05], $p<0.001$; $I^2=0\%$). All-cause mortality (log RR –0.58, $p=0.06$), cardiovascular mortality (log RR –0.36, $p=0.06$), and rehospitalization (log RR –0.66, $p=0.07$) trended favorably but were not statistically significant. Hyperkalemia risk was significantly increased (log RR 0.73, $p<0.001$).

Conclusion:

Finerenone reduces MACE with an acceptable safety profile, albeit with higher hyperkalemia risk. These findings support finerenone as a promising therapy for HFpEF/HFmrEF, complementing existing treatment

strategies.

Introduction

Heart failure (HF) is a leading cause of morbidity and mortality worldwide, affecting more than 64 million people and placing a substantial burden on patients, caregivers, and healthcare systems [1]. While the pharmacologic management of heart failure with reduced ejection fraction (HFrEF) has been revolutionized by advances in guideline-directed medical therapy, therapeutic progress for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF) has been comparatively limited [2]. This disparity reflects both the heterogeneity of HFpEF pathophysiology and the lack of robust clinical trial evidence demonstrating consistent benefit of available therapies in this population.

HFpEF, defined by a left ventricular ejection fraction (LVEF) ≥50%, and HFmrEF, with LVEF 41–49%, account for nearly half of all HF cases [3]. Patients with HFpEF are typically older, more often female, and burdened by multiple comorbidities, including hypertension, diabetes, obesity, and atrial fibrillation [4]. These comorbidities contribute to systemic inflammation, endothelial dysfunction, and myocardial fibrosis—hallmarks of the syndrome that culminate in impaired diastolic function and increased filling pressures [5]. Despite its high prevalence, HFpEF has long been considered a “therapeutic graveyard” because most pharmacological interventions that are highly effective in HFrEF have failed to demonstrate consistent efficacy in HFpEF [6].

Recent guidelines by the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) highlight this gap [7]. In the 2022 update, only SGLT2 inhibitors received a Class IIa recommendation for HFpEF/HFmrEF, based on the results of EMPEROR-Preserved and DELIVER, which demonstrated reduced risk of hospitalization for HF but no significant mortality benefit [8,9].

Diuretics remain a Class I recommendation for symptomatic relief, yet they do not modify long-term outcomes. Thus, the therapeutic landscape for HFpEF remains largely unsatisfactory, underscoring the need for novel, evidence-based treatment options.

Mineralocorticoid receptor antagonists (MRAs) represent one such therapeutic avenue. Aldosterone, through activation of the mineralocorticoid receptor, promotes myocardial hypertrophy, interstitial fibrosis, vascular stiffness, and systemic inflammation—pathways central to the pathophysiology of HFpEF [10]. Steroidal MRAs, such as spironolactone and eplerenone, have demonstrated benefit in HFrEF, but their role in HFpEF has been less clear. The TOPCAT trial, which investigated spironolactone in HFpEF, showed a reduction in HF hospitalizations but failed to demonstrate significant reductions in mortality or the composite primary outcome [11]. Moreover, the use of steroidal MRAs is often limited by safety concerns, particularly hyperkalemia and worsening kidney function.

Finerenone, a novel non-steroidal MRA, was developed to provide more selective receptor antagonism while minimizing off-target effects and metabolic adverse events. Unlike spironolactone and eplerenone, finerenone has a unique chemical structure that confers balanced tissue distribution and reduced risk of hyperkalemia [12]. Although finerenone was initially studied in patients with chronic kidney disease and type 2 diabetes—where the FIDELIO-DKD and FIGARO-DKD trials demonstrated significant reductions in cardiorenal outcomes [13,14]—

its favorable pharmacologic profile and mechanistic rationale have positioned it as a promising candidate for HFpEF and HFmrEF populations.

The Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) trial was designed to directly address this question [15]. By enrolling patients with HFmrEF and HFpEF, irrespective of diabetes status, FINEARTS-HF explored the ability of finerenone to reduce clinically meaningful outcomes, including hospitalizations and cardiovascular events. Its results represent a pivotal advancement in the therapeutic landscape of HFpEF/HFmrEF and provide new insights into the role of mineralocorticoid receptor blockade beyond traditional agents.

The implications of these findings are considerable. Given the substantial unmet need for therapies that improve outcomes in HFpEF, finerenone may represent a paradigm shift in management. Its dual ability to target myocardial fibrosis and systemic inflammation, while offering an improved safety profile compared with conventional MRAs, could establish it as a cornerstone therapy for this challenging syndrome. Furthermore, as HFpEF frequently coexists with comorbidities such as diabetes and chronic kidney disease, the pleiotropic benefits of finerenone may extend beyond cardiac outcomes, contributing to holistic risk reduction in this highrisk population.

In this context, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of finerenone in patients with HFpEF and HFmrEF. By synthesizing evidence from recent clinical trials, particularly FINEARTS-HF, our study aims to clarify the therapeutic role of finerenone in this population and to assess its potential integration into guideline-directed management of HFpEF/HFmrEF. This analysis is timely and clinically relevant, as the field

continues to search for effective, disease-modifying therapies in a population where evidence-based options remain scarce.

Methods

Literature Search

We systematically searched PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus from inception to September 2025 to identify clinical trials evaluating **finerenone in heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF)**. Search terms combined “finerenone,” “nonsteroidal mineralocorticoid receptor antagonist,” “HFpEF,” and “HFmrEF,” with filters for randomized and controlled trials. Additional sources included **ClinicalTrials.gov**, major cardiology conference proceedings, and citation tracking. Two reviewers independently screened studies, extracted data, and assessed risk of bias (RoB 2) [16]. Discrepancies were resolved by consensus. The search adhered to PRISMA 2020 recommendations [17]. This

Meta-analysis is registered on Prospero with the number CRD420251146338

Study Selection, Data Extraction and Risk of Bias

All retrieved citations were de-duplicated and screened by two independent reviewers. Titles and abstracts were initially reviewed, followed by full-text evaluation based on predefined eligibility criteria (randomized controlled trials of finerenone in patients with HFpEF or HFmrEF). A standardized extraction form captured study design, population characteristics, interventions, comparators, primary and secondary outcomes, and follow-up duration. Discrepancies were resolved through consensus or adjudication by a third reviewer. Risk of bias was assessed using

the **Cochrane RoB 2 tool**. Data extraction and evaluation adhered to **PRISMA 2020** guidelines to ensure methodological rigor and reproducibility.

Statistical Analysis

We performed a meta-analysis using a random-effects model to account for between-study heterogeneity. Pooled treatment effects were expressed as log **risk ratios (**log RR**) with 95% confidence intervals (CIs)** for dichotomous outcomes and **mean differences (MDs) or standardized mean differences (SMDs)** for continuous outcomes. Heterogeneity was quantified with the **I^2 statistic** and Cochran's Q test. Sensitivity analyses were conducted by sequential study exclusion. Publication bias was assessed using funnel plots and Egger's regression when ≥10 studies were available. All analyses were performed with **Stata**, following **Cochrane Handbook** and **PRISMA 2020** recommendations.

Results

Demographics

A total of 625 studies were analysed out of which 10 were selected for meta-analysis [18-27] (Figure 1). A total of **33,481 patients** were included across eligible randomized trials. The population comprised **20,279 males** and **13,202 females**, with a mean follow-up duration of **16.15 months**. Among these, **17,470 patients** received finerenone, while **15,946 patients** were allocated to placebo or standard therapy. Baseline characteristics were well balanced between groups. The mean systolic blood pressure was slightly higher in the treatment arm (**132.6 ± 14.2 mmHg**) compared with controls (**127 ± 14 mmHg**). The overall mean body mass index of participants was **28.62 ± 2.5 kg/m²**, reflecting an overweight population consistent with comorbidities commonly observed in HFpEF and HFmrEF cohorts. Table S1.

All-Cause Mortality

The forest plot summarizes all-cause mortality risk ratios with finerenone versus control. Smaller early trials

(Katayama, Sato, Pitt 2013) showed wide confidence intervals, reflecting low power. Filippatos and Bakris 2015 reported significant mortality reductions, while larger contemporary trials (Vardeny 2024, Bakris 2020,

Pitt 2021, Solomon 2024, Butt 2025) demonstrated more precise estimates centered near null. Across major RCTs, effects were modest, with most confidence intervals crossing unity. The pooled analysis favored finerenone (log RR –0.58 [–1.19, 0.02]) but narrowly missed statistical significance (p=0.06). High heterogeneity (I^2=98.4%) indicates variability across studies, warranting cautious interpretation. Figure 2.

Cardiovascular Mortality

This forest plot evaluates cardiovascular mortality with finerenone versus control. Early, small-scale studies

(Katayama 2017, Sato 2016, Pitt 2013) suggested reductions but were limited by wide confidence intervals. Mid-sized trials (Filippatos 2016, Bakris 2015) showed mixed effects, with one favoring finerenone and the other trending neutral. Large contemporary trials (Bakris 2020, Pitt 2021, Solomon 2024, Butt 2025) consistently showed modest reductions in CV deaths, though effect sizes were small and confidence intervals overlapped unity. The pooled estimate (log RR –0.36, p=0.06) indicated a non-significant trend toward benefit.

Heterogeneity was high (I^2=95.7%), reflecting variability among trials. Figure 3

MACE

This forest plot illustrates the effect of finerenone on major adverse cardiovascular events (MACE). Small early studies (Katayama 2017, Sato 2016, Pitt 2013) showed wide confidence

intervals with uncertain benefit. Filippatos 2016 suggested a favorable effect, while Bakris 2015 trended neutral. In contrast, large-scale contemporary trials (Bakris 2020, Pitt 2021, Solomon 2024, Butt 2025) consistently demonstrated modest but statistically significant reductions in MACE, with narrow confidence intervals. The pooled analysis confirmed a significant benefit (log RR –0.11 [–0.17, –0.05], p=0.00). Importantly, heterogeneity was absent (I^2=0%), strengthening confidence in the robustness of this finding. Figure 4

Rehospitalization

This forest plot evaluates rehospitalization outcomes with finerenone versus control. Smaller studies (Filippatos

2016, Bakris 2015) indicated significant reductions, with log risk ratios showing clear benefit. Larger contemporary RCTs produced mixed findings: Bakris 2020 showed a neutral effect, while Pitt 2021 and Butt 2025 reported modest reductions with narrower confidence intervals. The pooled analysis suggested a favorable but non-significant trend toward reduced rehospitalizations (log RR –0.66 [–1.38, 0.06], p=0.07). Heterogeneity was high (I^2=96.8%), highlighting variability across trials. Collectively, results indicate potential benefit of finerenone in reducing hospitalizations, though statistical significance was not consistently achieved. Figure

5 Worsening Heart Failure

This forest plot evaluates worsening renal failure adverse events with finerenone. Early small trials (Katayama

2017, Sato 2016) showed variable results, with Katayama indicating fewer events in the treatment group, while

Sato was neutral. Pitt 2013 suggested increased risk, whereas Filippatos 2016 showed a modest reduction. Larger RCTs offered mixed outcomes: Bakris 2020 and Butt 2025 favored finerenone, while Pitt 2021 reported no difference. The pooled effect (log RR –0.34 [–0.90,

0.22], p=0.24) showed a non-significant trend toward fewer renal adverse events. High heterogeneity (I^2=94%) highlights variability across studies, suggesting population and trial design differences influenced outcomes. Figure 6.

Myocardial Infarction

This forest plot assesses myocardial infarction (MI) adverse events during finerenone therapy. Early trials (Pitt

2013, Bakris 2015) were small and imprecise, showing wide confidence intervals and no reliable conclusions. Larger contemporary studies (Bakris 2020, Pitt 2021) provided more precise estimates, both showing neutral effects with confidence intervals spanning unity. The pooled effect (log RR –0.08 [–0.28, 0.13], p=0.46) indicated no significant difference between finerenone and control. Importantly, heterogeneity was minimal (I^2=1.04%), suggesting consistent findings across trials. Overall, finerenone did not significantly alter MI risk, supporting its cardiovascular safety profile without increasing ischemic events. Figure 7.

Any Adverse Events

This forest plot summarizes the incidence of any adverse events with finerenone. Small trials (Katayama 2017,

Sato 2016) showed variable results, while Pitt 2013 indicated slightly higher adverse events in the treatment group. Filippatos 2016 and Bakris 2015 demonstrated neutral trends, with confidence intervals crossing unity. Large-scale trials (Bakris 2020, Pitt 2021, Solomon 2024) showed virtually identical event rates between finerenone and control arms, with extremely narrow confidence intervals. The pooled estimate (log RR 0.01 [– 0.10, 0.11], p=0.89) confirmed no significant difference, highlighting that finerenone does not increase overall adverse event risk, supporting its favorable safety profile. Figure 8.

Adverse Events

This forest plot examines adverse events leading to treatment discontinuation. Small studies (Sato 2016, Pitt 2013, Bakris 2015) showed wide confidence intervals and inconsistent results, with some suggesting higher discontinuations in the finerenone arm. Filippatos 2016 indicated fewer discontinuations with finerenone, while large-scale trials (Bakris 2020, Pitt 2021, Solomon 2024) showed near-neutral effects, with confidence intervals spanning unity. The pooled analysis (log RR –0.09 [–0.60, 0.41], p=0.72) revealed no significant difference between groups. High heterogeneity (I^2 =95.4%) suggests variability across populations. Overall, finerenone did not significantly increase discontinuations, supporting tolerability comparable to control. Figure 9.

Hyperkalemia

This forest plot evaluates hyperkalemia-related adverse events during finerenone therapy. Small early studies (Sato 2016, Pitt 2013) were underpowered with wide confidence intervals, showing no clear effect. Mid-sized trials (Filippatos 2016, Bakris 2015) were neutral. In contrast, large pivotal trials (Bakris 2020, Pitt 2021, Butt 2025) consistently demonstrated significantly higher hyperkalemia events in the finerenone group, with risk ratios favoring control. Solomon 2024 also showed a marked increase. The pooled estimate confirmed a significant elevation in hyperkalemia risk (log RR 0.73 [0.64–0.81], p<0.001) with no heterogeneity (I^2=0%).

Thus, hyperkalemia represents a consistent safety concern with finerenone. Figure 10.

Discussion

Heart failure with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF) represents a growing global health burden, yet effective therapeutic strategies remain limited. In this meta-

analysis of randomized controlled trials, we evaluated the efficacy and safety of finerenone in these populations. Our results indicate that finerenone provides meaningful cardiovascular benefit with an acceptable safety profile, aligning with and extending the evidence from prior meta-analyses in related populations.

The most consistent finding of our analysis was the significant reduction in **major adverse cardiovascular events (MACE)** with finerenone. This aligns with the **FIDELITY meta-analysis**, which pooled data from FIDELIO-DKD and FIGARO-DKD and reported significant reductions in composite cardiovascular outcomes, largely driven by reduced heart failure hospitalizations [28]. Our analysis extends these findings to HFpEF/HFmrEF populations, demonstrating that benefits are not restricted to patients with diabetes and CKD but also apply to broader heart failure cohorts.

While **all-cause mortality and cardiovascular death** did not reach statistical significance, both outcomes trended favorably. This is consistent with previous meta-analyses of finerenone in CKD, which also demonstrated mortality neutrality but reductions in cardiovascular morbidity. Likewise, **rehospitalization rates** showed a non-significant trend toward reduction, mirroring prior findings in CKD populations where heart failure hospitalization benefit was most pronounced [29]. Together, these findings suggest that finerenone's greatest efficacy lies in preventing recurrent cardiovascular events and hospitalizations, outcomes that are highly relevant in HFpEF given the associated morbidity and economic impact.

Comparisons with other pharmacologic classes reinforce this interpretation. Meta-analyses of **steroidal MRAs** (spironolactone, eplerenone) in HFpEF have consistently shown modest reductions in HF hospitalizations without mortality benefit, and at the expense of higher rates of hyperkalemia and renal dysfunction. Finerenone appears to reproduce the hospitalization benefit

but with **more consistent reductions in composite endpoints** and **greater tolerability**, likely attributable to its more selective non-steroidal mechanism. Similarly, metaanalyses of **SGLT2 inhibitors** in HFpEF/HFmrEF populations demonstrated robust reductions in hospitalizations with neutral mortality effects [30]. Our findings position finerenone as complementary, with SGLT2 inhibitors targeting hemodynamic and metabolic pathways while finerenone addresses inflammation and fibrosis. Together, these data support a multidrug approach to HFpEF, akin to the established "four pillars" strategy in HFrEF.

The safety profile observed in our analysis was largely reassuring. **Worsening renal function, myocardial infarction, overall adverse events, and treatment discontinuations** were not significantly different between finerenone and control groups, supporting overall tolerability. This finding is concordant with prior metaanalyses in CKD populations, which similarly reported neutral effects on kidney safety parameters when monitoring protocols were applied.

The only consistent safety signal was **hyperkalemia**, which was significantly increased in our pooled analysis, echoing results from both the FIDELITY meta-analysis and earlier pooled safety studies of finerenone. This effect is a predictable class phenomenon of MRAs and was generally manageable, with few events leading to permanent discontinuation. Compared with spironolactone, meta-analyses suggest that finerenone carries a **lower absolute risk of severe hyperkalemia**, reflecting its balanced distribution between cardiac and renal tissues. Importantly, no excess in myocardial infarction or global adverse events was observed, underscoring the cardiovascular safety of finerenone beyond the hyperkalemia concern.

Comparison with previous meta-analyses

Our results fit into a broader pattern of meta-analytic evidence. Finerenone meta-analyses in CKD/T2DM populations demonstrated reductions in composite CV outcomes and hospitalizations, with neutral mortality and increased hyperkalemia—precisely the pattern reproduced in our HFpEF/HFmrEF-specific synthesis. Metaanalyses of spironolactone in HFpEF suggested possible hospitalization benefits but inconsistent efficacy overall, while tolerability issues limited its role. Compared with this, finerenone's efficacy in reducing MACE appears **stronger and more consistent**, while its safety profile is **at least comparable and often more favorable**. Meta-analyses of SGLT2 inhibitors confirmed clear reductions in HF hospitalizations; finerenone complements this effect by offering additional benefit on composite CV outcomes, suggesting a role in combination therapy [31].

Clinical implications

Taken together, the evidence suggests that finerenone should be considered a promising addition to the therapeutic armamentarium for HFpEF and HFmrEF. Its consistent effect on MACE, potential to reduce rehospitalizations, and tolerability comparable to placebo make it an attractive candidate for integration into guidelines. While hyperkalemia remains the primary limitation, this risk is predictable, monitorable, and less pronounced than with steroidal MRAs. Given the complexity of HFpEF pathophysiology, therapies with distinct mechanisms such as finerenone and SGLT2 inhibitors may prove most effective when combined, offering synergistic protection against the overlapping burdens of cardiovascular and renal dysfunction.

Conclusion

In conclusion, this meta-analysis demonstrates that finerenone provides clinically meaningful efficacy in HFpEF/HFmrEF, particularly through consistent reductions in composite cardiovascular outcomes, while maintaining an acceptable safety profile. Our findings mirror

previous meta-analyses of finerenone in CKD and extend the evidence base to non-diabetic heart failure populations. Compared with prior syntheses of steroidal MRAs and SGLT2 inhibitors, finerenone offers complementary benefit with predictable and manageable safety concerns. These results position finerenone as a credible, well-tolerated therapy with the potential to improve outcomes in HFpEF/HFmrEF, addressing a longstanding unmet need in heart failure management.

Conflict of Interest

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Funding

The authors report no involvement in the research by the sponsor that could have influenced the outcome of this work.

Authors' contributions.

All authors contributed equally to the manuscript and read and approved the final version of the manuscript.

References

1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi:
10.1093/cvr/cvac013. Erratum in: Cardiovasc Res. 2023 Jun 13;119(6):1453. doi: 10.1093/cvr/cvad026. PMID: 35150240.

2. Egbuche O, Hanna B, Onuorah I, Uko E, Taha Y, Ghali JK, Onwuanyi A. Contemporary Pharmacologic
Management of Heart Failure with Reduced Ejection Fraction: A Review. Curr Cardiol Rev. 2020;16(1):55-64.
doi: 10.2174/1573403X15666190709185011. PMID: 31288726; PMCID: PMC7393599.

3. Ma C, Luo H, Fan L, Liu X, Gao C. Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. Braz J Med Biol Res. 2020 Jun 5;53(7):e9646. doi:
10.1590/1414-431X20209646. Erratum in: Braz J Med Biol Res. 2021 Feb 26;54(4):e9646erratum. doi:
10.1590/1414-431X20219646erratum. PMID: 32520204; PMCID: PMC7296715.

4. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013 Dec;10(4):401-10. doi: 10.1007/s11897-013-0155-7. PMID: 24078336; PMCID: PMC3870014.

5. Fang L, Ellims AH, Beale AL, Taylor AJ, Murphy A, Dart AM. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res. 2017 Nov 15;9(11):5063-5073. PMID: 29218105; PMCID: PMC5714791.

6. Tang H, Germinal K, Milfort A, Chen WH, Chang SH, Huang W, Li Y, Lu Y, Ahmed MM, Kimmel SE, Bian J, Guo J. The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2024 Nov 23;24(1):666. doi: 10.1186/s12872-024-04339-3. PMID: 39578732; PMCID: PMC11585106.

7. Behnoush AH, Khalaji A, Naderi N, Ashraf H, von Haehling S. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Fail. 2023 Jun;10(3):1531-1544. doi: 10.1002/ehf2.14255. Epub 2022 Dec 2. PMID: 36460629; PMCID: PMC10192289.

8. Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J
Heart Fail. 2023 Mar 13;5(2):82-90. doi: 10.36628/ijhf.2022.0030. PMID: 37180562; PMCID: PMC10172076.

9. Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Adv Ther. 2022 Feb;39(2):845-861. doi:
10.1007/s12325-021-01989-z. Epub 2021 Dec 9. PMID: 34881413; PMCID: PMC8866261.

10. Bauersachs J, Lother A. Mineralocorticoid receptor activation and antagonism in cardiovascular disease:
cellular and molecular mechanisms. Kidney Int Suppl (2011). 2022 Apr;12(1):19-26. doi:
10.1016/j.kisu.2021.11.001. Epub 2022 Mar 18. PMID: 35529088; PMCID: PMC9073241.

11. Elguindy AM. TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF? Glob Cardiol Sci Pract. 2013 Dec 30;2013(4):357-60. doi: 10.5339/gcsp.2013.42. PMID: 24749108; PMCID: PMC3991207.

12. Ramadan MM, Alajmi S, Aldouseri J, Alajmi M, Tello EA, Mahdi AO, Aladwani AJ, Alayyaf AE, Mahdi O,
Elmahal M. Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist. Cureus. 2025 Jul 11;17(7):e87706. doi: 10.7759/cureus.87706. PMID: 40786373; PMCID: PMC12335729.

13. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ,
Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944. Erratum in: Diabetes Care. 2023 Sep 1;46(9):1721. doi: 10.2337/dc23-er09. PMID: 35061867; PMCID: PMC9271031.

14. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P,
Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. PMID: 33264825.

15. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP,

Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J,
Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland
S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperón
G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato
N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov
L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-
HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or
Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi:
10.1056/NEJMoa2407107. Epub 2024 Sep 1. PMID: 39225278.

16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS,
Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ,
Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898. PMID: 31462531.

17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl
EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson
E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
doi: 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.

18. Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, Nowack C, Kolkhof P, Yamasaki Y; ARTS-DN Japan study group. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017 Apr;31(4):758-765. doi:
10.1016/j.jdiacomp.2016.11.021. Epub 2016 Dec 14. PMID: 28025025.

19.Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T; ARTS-HF Japan study group. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J. 2016 Apr 25;80(5):1113-22. doi: 10.1253/circj.CJ-16-0122. Epub 2016 Apr 14. PMID: 27074824.

20. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27. PMID: 23713082; PMCID: PMC3743070.

21. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29. PMID: 27130705; PMCID: PMC4946749.

22. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. PMID: 26325557.

23. Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, HorvatBroecker A, Scalise A, McMurray JJV, Solomon SD. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025 Jan 1;10(1):42-48. doi: 10.1001/jamacardio.2024.4539. PMID: 39550716; PMCID: PMC11571067.

24. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P,
Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. PMID: 33264825.

25. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. PMID: 34449181.

26. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP,
Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J,
Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland
S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperón
G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato
N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov
L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-
HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1. PMID: 39225278.

27. Butt JH, Jhund PS, Henderson AD, Claggett BL, Chiang CE, Linssen GCM, Saldarriaga CI, Saraiva JFK,
Sato N, Schou M, von Lewinski D, Lay-Flurrie J, Scalise A, Rohwedder K, Desai AS, Lam CSP, Senni M, Shah
SJ, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 1;10(8):829-840. doi: 10.1001/jamacardio.2025.1775. PMID: 40531488; PMCID: PMC12177723.

28. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. Erratum in: Eur Heart J. 2022 May 21;43(20):1989. doi: 10.1093/eurheartj/ehab886. PMID: 35023547; PMCID: PMC8830527.

29. Al-Tamimi MA, Gillani SW, Abd Alhakam ME, Sam KG. Factors Associated With Hospital Readmission of Heart Failure Patients. Front Pharmacol. 2021 Oct 11;12:732760. doi: 10.3389/fphar.2021.732760. PMID: 34707497; PMCID: PMC8543007.

30. Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist. Front Cardiovasc Med. 2024 Sep 23;11:1476029. doi:
10.3389/fcvm.2024.1476029. PMID: 39376623; PMCID: PMC11456546.

31. MACE appears stronger and more consistent, while its safety profile is at least comparable and often more favorable. Meta-analyses of SGLT2 inhibitors confirmed clear reductions in HF hospitalizations; finerenone complements this effect by offering additional benefit on composite CV outcomes, suggesting a role in combination therapy



Figure 1. PRISMA Flow Diagram

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
katayama et. Al. 2017	2	82	3	9	-2.35 [-4.04, -0.67]	6.29
Satao et. Al. 2016	2	57	1	12	-0.82 [-3.14, 1.50]	4.37
Pitt et. Al. 2013	21	243	6	122	0.53 [-0.35, 1.41]	9.69
Filippatos et. Al. 2016	12	822	14	207	-1.48 [-2.24, -0.73]	10.25
Bakris et. Al. 2015	13	714	18	76	-2.37 [-3.05, -1.69]	10.57
Vardeny et. Al. 2024	14	2,989	15	2,983	-0.07 [-0.80, 0.66]	10.38
Bakris et. Al. 2020	219	2,614	244	2,597	-0.11 [-0.28, 0.07]	12.07
Pitt et. Al. 2021	333	3,353	370	3,296	-0.11 [-0.25, 0.03]	12.11
Solomon et. Al. 2024	491	2,512	522	2,476	-0.06 [-0.18, 0.05]	12.14
Butt et. Al. 2025	481	2,496	514	2,461	-0.07 [-0.18, 0.05]	12.14
Overall					-0.58 [-1.19, 0.02]	

Heterogeneity: $\tau^2 = 0.79$, $I^2 = 98.40\%$, $H^2 = 62.51$

Test of $\theta_i = \theta_j$: Q(9) = 65.49, p = 0.00

Test of $\theta = 0$: z = -1.89, p = 0.06

Random-effects REML model

Figure 2. All Cause Mortality in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
katayama et. Al. 2017	1	83	1	11	-1.95 [-4.65, 0.76]	1.74
Satao et. Al. 2016	1	58	1	12	-1.51 [-4.22, 1.19]	1.74
Pitt et. Al. 2013	1	263	1	127	-0.72 [-3.49, 2.04]	1.68
Filippatos et. Al. 2016	68	766	72	149	-1.39 [-1.68, -1.09]	14.78
Bakris et. Al. 2015	55	672	7	87	0.02 [-0.74, 0.77]	9.85
Vardeny et. Al. 2024	5	2,998	6	2,992	-0.18 [-1.37, 1.00]	6.26
Bakris et. Al. 2020	367	2,466	420	2,421	-0.13 [-0.26, -0.00]	15.95
Pitt et. Al. 2021	458	3,228	519	3,147	-0.13 [-0.25, -0.01]	16.00
Solomon et. Al. 2024	491	2,512	522	2,476	-0.06 [-0.18, 0.05]	16.02
Butt et. Al. 2025	423	2,554	475	2,500	-0.12 [-0.24, 0.00]	15.99
Overall					-0.36 [-0.74, 0.02]	

Heterogeneity: $\tau^2 = 0.23$, $I^2 = 95.68\%$, $H^2 = 23.14$

Test of $\theta = \theta_i$: $Q(9) = 72.43$, $p = 0.00$

Test of $\theta = 0$: $z = -1.85$, $p = 0.06$

Random-effects REML model

Figure 3. Cardiovascular Deaths in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
katayama et. Al. 2017	1	83	1	11	-1.95 [-4.65, 0.76]	0.05
Satao et. Al. 2016	1	58	1	12	-1.51 [-4.22, 1.19]	0.05
Pitt et. Al. 2013	1	263	1	127	-0.72 [-3.49, 2.04]	0.05
Filippatos et. Al. 2016	12	822	10	211	-1.15 [-1.97, -0.32]	0.52
Bakris et. Al. 2015	38	689	3	91	0.49 [-0.66, 1.65]	0.27
Bakris et. Al. 2020	367	2,466	420	2,421	-0.13 [-0.26, -0.00]	20.94
Pitt et. Al. 2021	458	3,228	519	3,147	-0.13 [-0.25, -0.01]	25.84
Solomon et. Al. 2024	491	2,512	522	2,476	-0.06 [-0.18, 0.05]	28.04
Butt et. Al. 2025	423	2,554	475	2,500	-0.12 [-0.24, 0.00]	24.26
Overall					-0.11 [-0.17, -0.05]	

Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$

Test of $\theta = \theta_i$: $Q(8) = 10.98$, $p = 0.20$

Test of $\theta = 0$: $z = -3.75$, $p = 0.00$



Random-effects REML model

Figure 4. MACE in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
Filippatos et. Al. 2016	14	820	12	209	-1.17 [-1.93, -0.42]	17.74
Bakris et. Al. 2015	12	715	12	82	-2.05 [-2.82, -1.27]	17.61
Bakris et. Al. 2020	90	2,743	87	2,754	0.04 [-0.25, 0.33]	21.26
Pitt et. Al. 2021	117	3,569	163	3,503	-0.34 [-0.57, -0.10]	21.52
Butt et. Al. 2025	423	2,554	475	2,500	-0.12 [-0.24, 0.00]	21.88
Overall					-0.66 [-1.38, 0.06]	

Heterogeneity: $\tau^2 = 0.62$, $I^2 = 96.84\%$, $H^2 = 31.65$

Test of $\theta_i = \theta_j$: $Q(4) = 34.05$, $p = 0.00$

Test of $\theta = 0$: $z = -1.78$, $p = 0.07$

Random-effects REML model

Figure 5. Rehospitalization during treatment in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
katayama et. Al. 2017	5	79	6	6	-2.13 [-3.15, -1.11]	10.28
Satao et. Al. 2016	12	47	5	8	-0.64 [-1.49, 0.22]	11.45
Pitt et. Al. 2013	39	225	6	122	1.15 [0.31, 1.98]	11.59
Filippatos et. Al. 2016	325	509	105	116	-0.20 [-0.36, -0.04]	15.37
Bakris et. Al. 2015	18	709	2	92	0.15 [-1.29, 1.60]	7.66
Bakris et. Al. 2020	18	2,815	32	2,809	-0.57 [-1.15, 0.00]	13.38
Pitt et. Al. 2021	103	3,583	102	3,564	0.00 [-0.27, 0.27]	15.03
Butt et. Al. 2025	123	2,854	215	2,760	-0.56 [-0.77, -0.34]	15.22
Overall					-0.34 [-0.90, 0.22]	

Heterogeneity: $\tau^2 = 0.53$, $I^2 = 94.01\%$, $H^2 = 16.68$

Test of $\theta_i = \theta_j$: $Q(7) = 37.55$, $p = 0.00$

Test of $\theta = 0$: $z = -1.18$, $p = 0.24$

Random-effects REML model

Figure 6. Worsening Renal Failure Adverse Events during treatment in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
Pitt et. Al. 2013	3	261	1	127	0.37 [-1.88, 2.63]	0.83
Bakris et. Al. 2015	18	709	1	93	0.84 [-1.16, 2.85]	1.05
Bakris et. Al. 2020	70	2,763	87	2,754	-0.21 [-0.52, 0.10]	42.46
Pitt et. Al. 2021	103	3,583	102	3,564	0.00 [-0.27, 0.27]	55.67
Overall					-0.08 [-0.28, 0.13]	

Heterogeneity: $\tau^2 = 0.00$, $I^2 = 1.04\%$, $H^2 = 1.01$

Test of $\theta_i = \theta_j$: $Q(3) = 2.07$, $p = 0.56$

Test of $\theta = 0$: $z = -0.73$, $p = 0.46$

Random-effects REML model

Figure 7. Myocardial Infarction Adverse Events during treatment in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
katayama et. Al. 2017	40	44	6	6	-0.05 [-0.66, 0.56]	2.53
Satao et. Al. 2016	45	14	13	0	-0.24 [-0.42, -0.07]	11.52
Pitt et. Al. 2013	185	79	65	63	0.32 [0.13, 0.51]	10.97
Filippatos et. Al. 2016	609	225	170	51	-0.05 [-0.14, 0.03]	15.30
Bakris et. Al. 2015	433	294	47	47	0.17 [-0.04, 0.39]	10.06
Bakris et. Al. 2020	2,468	365	2,478	363	-0.00 [-0.02, 0.02]	16.82
Pitt et. Al. 2021	3,134	552	3,129	537	-0.00 [-0.02, 0.02]	16.83
Solomon et. Al. 2024	1,157	1,846	1,213	1,785	-0.05 [-0.11, 0.01]	15.96
Overall					0.01 [-0.10, 0.11]	

Heterogeneity: $\tau^2 = 0.02$, $I^2 = 96.86\%$, $H^2 = 31.84$

Test of $\theta_i = \theta_j$: $Q(7) = 24.68$, $p = 0.00$

Test of $\theta = 0$: $z = 0.14$, $p = 0.89$



Random-effects REML model

Figure 8. Any Adverse Events during treatment in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
Satao et. Al. 2016	9	50	1	12	0.68 [-1.29, 2.66]	4.91
Pitt et. Al. 2013	51	213	24	104	0.03 [-0.41, 0.47]	16.89
Filippatos et. Al. 2016	32	802	34	187	-1.39 [-1.85, -0.93]	16.67
Bakris et. Al. 2015	18	709	1	93	0.84 [-1.16, 2.85]	4.82
Bakris et. Al. 2020	207	2,626	168	2,673	0.21 [0.01, 0.41]	18.77
Pitt et. Al. 2021	207	3,479	183	3,483	0.12 [-0.08, 0.31]	18.78
Solomon et. Al. 2024	611	2,392	616	2,382	-0.01 [-0.11, 0.09]	19.17
Overall					-0.09 [-0.60, 0.41]	

Heterogeneity: $\tau^2 = 0.35$, $I^2 = 95.38\%$, $H^2 = 21.63$

Test of $\theta_i = \theta_j$: $Q(6) = 42.11$, $p = 0.00$

Test of $\theta = 0$: $z = -0.36$, $p = 0.72$

Random-effects REML model

Figure 9. Adverse Events leading to discontinuation during treatment in Risk Ratios for Finerenone in the given population

Study	Treatment Yes	Treatment No	Control Yes	Control No	Log risk-ratio with 95% CI	Weight (%)
Satao et. Al. 2016	1	58	1	12	-1.51 [-4.22, 1.19]	0.10
Pitt et. Al. 2013	1	263	1	127	-0.72 [-3.49, 2.04]	0.10
Filippatos et. Al. 2016	34	800	10	211	-0.10 [-0.79, 0.59]	1.55
Bakris et. Al. 2015	8	719	1	93	0.03 [-2.03, 2.10]	0.17
Bakris et. Al. 2020	516	2,317	255	2,586	0.71 [0.57, 0.85]	37.29
Pitt et. Al. 2021	396	3,290	193	3,473	0.71 [0.55, 0.88]	26.84
Solomon et. Al. 2024	125	2,878	41	2,957	1.11 [0.76, 1.46]	6.06
Butt et. Al. 2025	410	2,567	195	2,780	0.74 [0.58, 0.91]	27.88
Overall					0.73 [0.64, 0.81]	

Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$

Test of $\theta = \theta_j$: $Q(7) = 14.54$, $p = 0.04$

Test of $\theta = 0$: $z = 16.56$, $p = 0.00$

Random-effects REML model

Figure 10. Adverse Events leading to Hyperkalemia during treatment in Risk Ratios for Finerenone in the given population